XPO1 Inhibition Using Selinexor Synergizes With Chemotherapy in Acute Myeloid Leukemia (AML) by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus

PURPOSE: Selinexor, a selective inhibitor of XPO1, is currently being tested as single agent in clinical trials in acute myeloid leukemia (AML). However, considering the molecular complexity of AML, it is unlikely that AML can be cured with monotherapy. Therefore we asked whether adding already esta...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Clin Cancer Res
Autores principales: Ranganathan, Parvathi, Kashyap, Trinayan, Yu, Xueyan, Meng, Xiaomei, Lai, Tzung-Huei, McNeil, Betina, Bhatnagar, Bhavana, Shacham, Sharon, Kauffman, Michael, Dorrance, Adrienne M., Blum, William, Sampath, Deepa, Landesman, Yosef, Garzon, Ramiro
Formato: Artigo
Lenguaje:Inglês
Publicado: 2016
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5161584/
https://ncbi.nlm.nih.gov/pubmed/27358488
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-2885
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares